Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
390.00    2.00 (0.52%)
Bid:
385.00
Ask:
395.00
Spread: 10.00 (2.597%)
Market Cap: £187.19m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Pre-close trading update

28 Jul 2014 07:00

RNS Number : 4208N
Tristel PLC
28 July 2014
 



 

28 July 2014

Tristel plc

("Tristel" or the "Company")

 

Pre-close trading update and notice of results

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, provides a trading update following the end of its financial year on 30 June 2014. Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.

 

The Company enjoyed a strong second half performance which has led to a fifth profit upgrade this financial year. The preliminary results for the year ended 30 June 2014 will be released on 13 October 2014 and will show revenues and pre-tax profit ahead of expectations that were last updated in June. 

 

Trading highlights

· H2 revenues of £7.04m up by 9.3% on H1 (£6.44m)

· Full year revenues of £13.48m up 27.7% on previous year (2013: £10.56m) 

· Full year pre-tax profit of £1.8m before share based payments (2013: adjusted* pre-tax profit of £0.48m)

· Net cash of £2.59m at 30 June (2013: £0.49m)

 

*Adjusted for non-recurring items of £2.2m

 

Paul Swinney, Chief Executive, comments "The Company ended its financial year in good shape. The improved performance achieved over the past twelve months relates to all areas of the Group and is expected to continue into the new financial year and beyond."

 

For further information please contact:

 

Tristel plc

www.tristel.com

Paul Swinney, Chief Executive Officer

Tel: 01638 721 500

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07854 391 303

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Stephen Norcross (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDELFLZDFEBBZ
Date   Source Headline
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
31st Mar 20258:56 amRNSHolding(s) in Company
26th Mar 202510:30 amRNSDirector/PDMR Shareholding
18th Mar 20252:39 pmRNSHolding(s) in Company
24th Feb 20257:00 amRNSUnaudited Interim Results
7th Feb 20257:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20257:00 amRNSDirector Option Grant
13th Jan 20257:00 amRNSConfirmation of Interim Results
16th Dec 20242:45 pmRNSResult of AGM
16th Dec 20247:00 amRNSAGM Statement and Notice of Interim Results
22nd Nov 202410:30 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Nov 20241:32 pmRNSExercise of Share Options and Total Voting Rights
20th Nov 20248:47 amRNSExercise of Share Options and Total Voting Rights
28th Oct 20241:37 pmRNSExercise of Share Options and Total Voting Rights
21st Oct 20247:00 amRNSFinal Results
1st Oct 20247:00 amRNSNotice of Preliminary Results
20th Sep 20247:00 amRNSDirector/PDMR Shareholding
19th Sep 20241:13 pmRNSExercise of Share Options and Total Voting Rights
12th Sep 20247:00 amRNSFDA 510(k) submission for Tristel OPH
2nd Sep 20247:00 amRNSConfirmation of CEO Transition, Directorate Change
6th Aug 20243:32 pmRNSExercise of Share Options and Total Voting Rights
22nd Jul 20247:00 amRNSTrading Update
4th Jul 20243:43 pmRNSExercise of Share Options and Total Voting Rights
11th Jun 20245:48 pmRNSDirector/PDMR Shareholding
11th Jun 20243:50 pmRNSHolding(s) in Company
10th Jun 20247:00 amRNSAppointment of CEO
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.